Business
Relmada Therapeutics Provides Regulatory Update Confirming FDA Alignment on Registrational Studies Design for NDV-01 for Two Separate Indications
FDA written feedback supports: - a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS - a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting Phase 3 program expected to initiate in 1H 2026 CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous sy
About this update from Relmada Therapeutics, Inc.
[{"type":"image","alt":"Relmada Therapeutics","displaySize":"","headline":null,"caption":"Relmada Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/1e6b0a87f8dab0f1d062695dd08847ff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/0268YsqVciKwgjFbGEosKg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1e6b0a87f8dab0f1d062695dd08847ff","width":300,"height":75}},"lazy":false},{"type":"text","content":"FDA written feedback supports:","length":30,"tagName":"p"},{"type":"text","content":"- a single-arm, open-label registrational trial in 2nd-line refractory high-grade NMIBC with CIS","length":96,"tagName":"p"},{"type":"text","content":"- a randomized vs observation single trial in intermediate-risk NMIBC in the adjuvant setting","length":93,"tagName":"p"},{"type":"text","content":"Phase 3 program expected to initiate in 1H 2026","length":47,"tagName":"p"},{"type":"text","content":"CORAL GABLES, Fla., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that it has received written feedback from the U.S. Food and Drug Administration (FDA) regarding the registrational development pathway for NDV-01 in 2nd-line refractory, high-grade BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) -- one of the highest-risk and most treatment-resistant NMIBC populations -- and in intermediate risk NMIBC in the adjuvant setting, where there are currently no approved therapies.","length":714,"tagName":"p"},{"type":"text","content":"In its written response to Relmada’s Type B pre-IND submission, the FDA indicated that a single-arm, open-label clinical trial in this high-grade, BCG-unresponsive with CIS population is an appropriate registrational approach for NDV-01. This feedback provides a clear and efficient development path toward a potential NDA submission for NDV-01 as a bladder-sparing therapeutic option in a patient population with significant unmet need.","length":437,"tagName":"p"},{"type":"text","content":"The FDA also provided separate, supportive written feedback on the Company’s planned single...